Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Leuk Lymphoma. 2019 Nov 12;61(3):660–667. doi: 10.1080/10428194.2019.1688323

Table 2.

Ruxolitinib Naïve Control Cohort Therapies

Myelofibrosis N=57
 No pharmacological intervention 26 (45.6%)
 Hydroxyurea 8 (14%)
 Anagrelide 3 (5.3%)
 Danazol 3 (5.3%)
 Peginterferon alfa-2a 3 (5.3%)
 Darbepoetin alfa 2 (3.5%)
 Decitabine 2 (3.5%)
 LBH589 2 (3.5%)
 Thalidomide 2 (3.5%)
 Busulfan 1 (1.8%)
 KB004 1 (1.8%)
 Luspatercept 1 (1.8%)
 Melphalan 1 (1.8%)
 Pomalidomide 1 (1.8%)
 PRM-151 1 (1.8%)
Non-myelofibrosis N=16
 Hydroxyurea 10 (62.5%)
 Peginterferon alpha-2a 4 (25%)
 Anagrelide 2 (12.5%)